Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer
Twenty patients with small cell lung cancer (SCLC) were entered to the study. Fourteen cases were male and six cases were female. Twelve cases were extensive disease, eight cases were limited disease. Median age was 60 years (range = 40-72 years), median performance status was 70 per cent (range = 6...
Saved in:
Main Author: | Thongprasert S. |
---|---|
Format: | Clinical Trial |
Language: | English |
Published: |
2014
|
Online Access: | http://www.ncbi.nlm.nih.gov/pubmed/3502482 http://cmuir.cmu.ac.th/handle/6653943832/3310 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Language: | English |
Similar Items
-
Phase II study of paclitaxel (Taxol) and ifosfamide (Holoxan) in inoperable non-small-cell lung cancer
by: Thongprasert S.
Published: (2014) -
Phase II study of three days' fractionated dosage of ifosfamide, epirubicin and cisplatin in small cell lung cancer
by: Thongprasert S., et al.
Published: (2014) -
Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014) -
Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014) -
Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
by: Sumitra Thongprasert, et al.
Published: (2018)